Monoclonal antibodies (mAbs) are currently the largest and fastest growing class of biopharmaceuticals, and they address unmet medical needs, e.g., in oncology and in auto-immune diseases. Their clinical efficacy and safety is significantly affected by the structure and composition of their glycosylation profile which is commonly heterogeneous, heavily dependent on the manufacturing process, and thus susceptible to variations in the cell culture conditions. Glycosylation is therefore considered a critical quality attribute for mAbs. Commonly, in currently marketed therapeutic mAbs, the glycosylation profile is suboptimal in terms of biological properties such as antibody-dependent cell-mediated cytotoxicity or may give rise to safety concerns due to the presence of non-human glycans. This article will review recent innovative developments in chemo-enzymatic glycoengineering, which allow generating mAbs carrying single, well-defined, uniform Fc glycoforms, which confers the desired biological properties for the target application. This approach offers significant benefits such as enhanced Fc effector functions, improved safety profiles, higher batch-to-batch consistency, decreased risks related to immunogenicity and manufacturing process changes, and the possibility to manufacture mAbs, in an economical manner, in non-mammalian expression systems. Overall, this approach could facilitate and reduce mAb manufacturing costs which in turn would translate into tangible benefits for both patients and manufacturers. The first glycoengineered mAbs are about to enter clinical trials and it is expected that, once glycoengineering reagents are available at affordable costs, and in-line with regulatory requirements, that targeted remodeling of antibody Fc glycosylation will become an integral part in manufacturing the next-generation of immunotherapeutics.
Introduction
Recombinant monoclonal antibodies (mAbs) are one of the most important class of biotherapeutics. Rising incidences of cancer and other chronic diseases are engendering a high demand for biologics, which is serving as the key contributing factor for the growth of this industry. Since 1984, more than 60 mAbs and fusion molecules have been approved by the US Food and Drug Administration (FDA) for over 30 targets in cancer, autoimmune and cardiovascular diseases (Shepard et al. 2017) . In a recent market research study, the global monoclonal antibody market was valued at USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion by 2024 (http://www.grandviewresearch.com/ pressrelease/global-monoclonal-antibodies-market).
Historically, monoclonal antibody development has been driven by efforts to provide patients with safer and more efficacious products through gradual improvements over time in terms of both reduced immunogenicity and increased potency. The first generation mAbs were 100% murine and immunogenic in human, and therefore not suited for chronic therapy. Successively, chimeric (approximately 35% murine), humanized (approximately 7% murine) and fully human (0% murine) antibodies were developed over time in order to decrease mAb immunogenicity. However, despite such efforts, even fully human antibodies such as adalimumab, the bestselling antibody drug on the market, were still reported to be immunogenic (Matucci et al. 2016 ). Moreover, a recent review on the evidence of benefits on the overall survival and the quality of life of approved cancer drugs, including a number of mAbs, concluded that most of the drugs that entered the market between 2009 and 2013 showed only marginal gains in terms of overall survival and quality of life (Davis et al. 2017) . A similar study on cancer treatments, approved by the FDA, concluded that only a small proportion of these drugs unequivocally show benefits on the survival and the quality of life (Kim and Prasad 2016) . These studies therefore underscore the necessity to introduce new oncology mAbs with maximized efficacy and safety profile which in turn translate into clear benefits such as the survival and/or the quality of life of patients.
Most of the mAb therapeutics are glycosylated, although nonglycosylated forms exist, e.g., when effector functions are not desired. The present paper focusses on glycosylated mAbs.
IgG Fc glycosylation -structural and functional properties
Monoclonal antibodies are mainly based on the prototypic antibody structure of IgG1, the most abundant serum subclass of γ-immunoglobulins. An IgG1 antibody is composed of two identical heavy (H) chains (50 kDa) and two identical κ or λ light (L) chains (25 kDa), linked together by inter-molecular disulfide bonds. Each heavy chain consists of an N-terminal variable domain (VH) followed by three constant domains (CH1, CH2, CH3). The so-called hinge region, linking the CH1 and the CH2 domains, contains the cysteines residues making up the four intermolecular disulfide bonds (two between the two heavy chains H=H and two between the heavy chain and light chain 2H-L), and confers the typical Y-shaped quaternary structure of IgG1s (Figure 1) .
Each of the two CH2 domains of the heavy chains contains a conserved IgG-Fc N-glycan site (position Asn 297 according to the EU numbering). The IgG-Fc overall shape resembles that of a horseshoe. Most of the internal Fc space between the two CH2 domains is filled by the two oligosaccharide chains (Figure 1 ) which engage in glycan-glycan and glycan-protein interactions (Figure 2) .
The Fc-glycans dictate stability (Bowden et al. 2012) , conformation and spacing between the two CH2 low hinge regions. Consequently, they are implicated in the binding properties with complement factor (C1q) and Fc gamma receptors (FcγRs, including the activating receptors FcγRI, FcγRIIa, FcγRIIc, FcγRIIIa and FcγRIIIb, and the inhibitory receptor FcγRIIb) (Idusogie et al. 2000; Krapp et al. 2003; Schneider and Zacharias 2012) . Furthermore, they impact on the opening/closure of the CH2-CH3 pivot region responsible for the binding to the neonatal Fc receptor (FcRn) and the type II receptors (including DC-SIGN (Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing) and CD23) (Pincetic et al. 2014) , and the susceptibility to enzymatic degradation (Zheng et al. 2014; Falck et al. 2015) .
By masking hydrophobic residues, they also decrease aggregation propensity which was found to be higher in non-glycosylated mAbs (Kayser et al. 2011) . The manner in which the Fc glycans are embedded in the protein structure gives rise to structural fluctuations which are more dynamic than previously assumed (Meier and Duus 2011) ; they allow various Fc conformational states (Frank et al. 2014) with the potential to expose or shield large parts of the protein surface, and making a buried glycan accessible to processing enzymes or binding proteins (Meier and Duus 2011) . The Fc glycans are therefore crucial for the Fc structure and the resulting multiple Fc effector functions (Jefferis 2012 (Euler and Alter 2015) . The dynamic modulation of the two CH2 low hinge regions, induced by the Fc glycans, plays a key role in the antibody interaction with the Fcγ receptors and the C1q, allowing a finetuned communication with the immune system cells, e.g., providing instructions to the innate immune system on how (by antibodydependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), or complement-dependent cytotoxicity (CDC) it should destroy the cells to which that antibody is bound. These effector functions play a pivotal role in the mAbs used Fig. 1 . Human IgG1 3D structure. The heavy chains are shown in blue and light blue, the light chains are shown in red and light red, respectively. The 2 N-glycans, present at each of the two heavy chains, are illustrated in a solid sphere representation with different colors (gray and yellow). The illustration was generated by rendering the PDB entry 1hzh by using the PyMOL Molecular Graphic System version 1.8.6.0. Schrödinger, LLC. Each light chain consists of an Nterminal variable domain (VL) and a constant domain (CL). Two heavy chainlight chain heterodimers combine into a single antibody molecule (H2L2). The light chain is associated to the VH and the CH1 domains to form the fragment antigen binding (Fab) region. The C-terminal part of the antibody, formed by (CH2-CH3)2 domains, is called fragment crystallizable (Fc) region. The variable region of the Fab is responsible for the capability of immunoglobulins of binding to an antigen, while the Fc part, which contains the binding sites for the complement component 1q (C1q) and the Fc-γ-receptors (FcγRs), is responsible for the antibody effector functions such as the antibody-dependent cell-mediated cytotoxicity (ADCC), the antibody-dependent cell-mediated phagocytosis (ADCP), and the complement-dependent cytotoxicity (CDC). In addition, the Fc region contains two Fc neonatal receptor (FcRn) binding sites which are responsible for the long antibody half-life (Vidarsson et al. 2014; Quast et al. 2017 ).
in oncology and contribute to the clearance of cancer cells. For example, the abovementioned effector functions are all part of the mode of action (MoA) of rituximab, the first mAb approved (1997) for cancer treatments (Jaglowski et al. 2010) .
The glycan residues on the 1-6 and 1-3 arm of each Fc-N-glycan are characterized by differential interactions and mobility (Krapp et al. 2003; Fortunato and Colina 2014) . The 1-6 arm is more rigid, while the 1-3 arm is more flexible (Figure 2) .
The galactose on the 1-3 arm has a high mobility and is more accessible to human alpha2-6 sialyltransferase (ST6), leading to an innate 1-3 arm preferential sialylation also on released glycans (Barb et al. 2009 ). On the contrary, galactose on the 1-6 arm is involved in four hydrogen bonds which decrease the mobility and further stabilize the Fc structure (Raju 2008) . It has been reported that galactosylated mAbs have different properties in terms of Fab orientation (distribution of directional and rotational vectors) as well as distribution of radii of gyration in comparison with agalactosylated mAbs (Fortunato and Colina 2014) . This may further translate in a differential impact on the functional properties of galactosylated in comparison with agalactosylated antibodies.
The Fc oligosaccharides and their 1-3 and 1-6 arm combination represent a special case among glycoproteins with almost each of the oligosaccharide components directly or indirectly eliciting structural or functional effects. The binding stoichiometry between mAbs and FcγRs or C1q is 1:1, while between mAbs and FcRn or type II receptors it is 1:2 (Pincetic et al. 2014) .
Functional impact of sialylation and galactosylation. An intriguing aspect of Fc-glycans is the differential impact of sialic acid linkage 2,6 vs. 2,3 on the anti-inflammatory properties of antibodies (Anthony, Nimmerjahn, et al. 2008; Anthony, Wermeling, et al. 2008; Sondermann et al. 2013) . Human endogenous Fcglycans contain exclusively 2,6-linked sialic acid residues. Fc-2,6 sialylated glycans allow the Fc domain to interconvert between an open and a closed conformation, thus increasing its conformational plasticity and introducing novel functional properties, e.g., the capacity of the closed conformation to bind to the type II receptors DC-SIGN and CD23 (Sondermann et al. 2013; Pincetic et al. 2014) . In this manner, the 2,6 sialic acid confers anti-inflammatory properties to IgG (Anthony, Wermeling, et al. 2008; Scanlan et al. 2008; Anthony and Ravetch 2010; Anthony et al. 2012) . On the contrary, CHO cell lines (unless genetically modified (El Mai et al. 2013; Yang et al. 2015) cannot produce 2,6 sialylated glycans. Instead, they produce only glycans with 2,3 sialic acid linkages, which however do not have anti-inflammatory properties (Anthony, Nimmerjahn, et al. 2008; Anthony, Wermeling, et al. 2008) . For intravenous immunoglobulins (IVIGs), which are used for the treatment of different auto-immune diseases, and which commonly contain comparatively low sialylation levels (<10%) (Huang et al. 2012 ), 2,6 sialylation has been reported to improve anti-inflammatory properties (Anthony and Ravetch 2010) .
Galactosylation is also implicated with anti-inflammatory properties. Highly galactosylated, as opposed to agalactosylated immune-complexes, bind to the FcγRIIB and suppress the complement component 5a receptor 1-related (C5aR) pro-inflammatory properties during complement activation (Karsten et al. 2012) . Consequently, both galactosylated and 2,6 sialylated Fc-glycoforms can modulate the suppression of the inflammatory responses. On the contrary, immune-complexes formed by agalactosylated Fcglycoforms are pro-inflammatory as they can only activate the activating FcγRs (Nimmerjahn and Ravetch 2010; Karsten et al. 2012; Collin and Ehlers 2013) but not the inhibitory FcγRIIB. Fc-glycan removal ablates both anti-and pro-inflammatory responses (Kaneko et al. 2006; Anthony and Nimmerjahn 2011; Albert et al. 2008 ). This underscores the relevance of the Fc-glycans in fine-tuning the interactions of the Fc domain with its cognate receptors and thus, in their regulation (Pincetic et al. 2014 ). Consequently, both 2,6 sialylated (S2(α2,6)G2F) and galactosylated (G2F) Fc-glycans are contributing factors to the anti-inflammatory properties of antibodies.
Differently from endogenous antibodies, which generally contain higher levels of galactosylated and 2,6 sialylated glycans, commercial antibody therapeutics commonly contain mainly agalactosylated glycans (Jefferis 2012; Batra and Rathore 2016) , and this can be expected to clearly differentiate their anti-inflammatory and functional properties.
Generally, the Fc glycosylation is considered not to directly affect the mAb's interaction with the FcRn (Pawlowski et al. 2018 ). However, indirectly, specific glycan chains may indeed have a potential role on the FcRn-mediated clearance given the Fab interaction with the FcRn (Jensen et al. 2017) , the impact of the Fc-glycan residues on the Fab orientation (Fortunato and Colina 2014) , as well as the potential modulation of opening/closure of the FcRn binding site . Also, patient-related factors influence the impact of the Fc glycans on efficacy, safety and immunogenicity of therapeutic mAbs. There will be a differential impact depending on the type (soluble or membrane-bound), and specificity of the target, the indication, the patient's FcγRs genetic polymorphism, and the potential presence of pre-existing antibodies against certain glycoforms in a given patient population, e.g., antiagalactosyl, anti-galactose-α-1,3-galactose (anti-α-gal), anti-N-glycolylneuraminic acid (anti-NGNA) (Zhu and Hurst 2002; Lu et al. 2007; Macher and Galili 2008) . Given the relatively high content of agalactosylated glycans in commercial, fully human mAbs, such as adalimumab (Raju and Jordan 2012) , it might be speculated that their observed immunogenicity can, in part, be attributed to the presence of pre-existing antibodies against the agalactosylated glycoforms in RA patients (Lu et al. 2007 ), or to the immunogenic potential of the agalactosylated/high-mannose glycoforms which have the ability to engage with mannose receptors on dendritic cells (Dong et al. 1999) .
Regarding ADCC, controversial results have been reported on the impact of galactosylation, e.g., no impact (Boyd et al., 1995; Shinkawa et al. 2003) , or positive impact (Houde et al. 2010) . The controversial ADCC results may be explained by the differential impact of galactose on the two arms (1-6 and/or 1-3) of the Fc-glycan; the galactose on the 1-6 arm has been associated with the enhanced ADCC, while the opposite has been observed when present on the 1-3 arm (Chung et al. 2014) . Of interest, Houde clearly showed the significantly higher binding to FcγRIIIa, compared to the wild-type, when the mAb was non-fucosylated and hypergalactosylated (approximately an 80-fold increase) in comparison to the non-fucosylated agalactosylated glycoform (approximately a 40-fold increase) (Houde et al. 2010) . Furthermore, it has been suggested that a particular pairing of oligosaccharides is necessary for the optimum binding of IgG to C1q, FcγRs. The apparent contradiction among some glycosylation data may thus partially be due to the lack of information of the mode of pairing of the two oligosaccharides. The Fc portion can be asymmetric as well as symmetric with respect to glycosylation, and the different pairing adds further complexity to the functional studies. The information concerning the pairing of the Fc-glycan is also relevant in understanding the biological significance of the heterogeneities of the IgG glycans (Masuda et al. 2000) .
The level of galactosylation was also found to be correlated with ADCP with higher galactosylation levels resulting in stronger ADCP (Chung et al. 2014 ).
An enzymatic approach to study the functional impact of glycovariants has been reported by Thomann in which the same starting material can be degalactosylated, hypergalactosylated and sialylated by using commercially available enzymes and activated sugars (Thomann et al. 2015) . The above study clearly shows the relevance of galactosylation on ADCC which is higher in fucosylated hypergalactosylated glycans.
Endogenous human IgG1 and differences with commercial, cell culture-derived mAbs. Regarding the overall Fc-glycan composition, the endogenous IgG1 glycan structures are almost completely biantennary complex glycans (99.4% complex, 0.6% hybrid, <0.1% HM) with an extensive micro-heterogeneity due to the presence or absence of different terminal sugars: Sialic acid, Gal, GlcNAc, core Fuc and bisecting GlcNAc. Total agalactosylated glycoforms (G0+G0F+G0FB) were found at a level of approximately 16% (Flynn et al. 2010 ).
However, elevated levels of agalactosylated glycans are found in humans under specific conditions such as aging, inflammatory and autoimmune diseases (Dall'Olio et al. 2013) . Moreover, in rheumatoid arthritis (RA) patients, elevated levels of anti-agalactosylated IgG and Rheumatoid Factors (RF) are present, which bind preferentially to the agalactosylated glycoforms (Ichikawa et al. 1998) .
During pregnancy, changes in the maternal immune adaptation are required to tolerate the fetus, and to initiate and maintain a successful pregnancy. Changes include an increased level of galactosylation in the Fc glycan profile of IgG in both healthy individuals and RA patients (Ruhaak et al. 2014) . RA patients experience amelioration of symptoms during pregnancy, followed by a worsening after delivery, which leads to a decrease in the galactosylation level. In RA patients during pregnancy, galactosylation, but not sialylation, is associated with lower disease activity (Bondt et al. 2013 ).
In the serum of patients suffering from rheumatoid arthritis and other autoimmune diseases, agalactosylated IgGs are present in abundance. This, together with the observation that arthritis-like symptoms could be induced by the infusion of agalactosylated IgG, but not by G2 IgG, into non-diseased murine recipients, lead to the hypothesis that agalactosylated IgG play a potential role in the disease pathogenesis (Dong et al. 1999) . A potential explanation suggested the involvement of the mannose receptor, which is expressed on macrophages and dendritic cells, which binds glycans containing exposed fucose, mannose, and N-acetylglucosamine residues (e.g., agalactosylated glycoforms). Ligand uptake is continuous, due to receptor recycling, allowing the intracellular processing of large quantities of ligands (Dong et al. 1999 ). The dendritic cell uptake of agalactosylated IgG, but not G2 IgG, was highly efficient (within 15 min after exposure of ligands), and was inhibited by mannose (Dong et al. 1999) . The processing and the presentation of agalactosylated IgG-derived peptides could stimulate CD4+ T-cell responses. Therefore, the agalactosylated and the high mannose IgG glycoforms may potentially alter function, safety, catabolism and antigenicity.
As mentioned above, most commercial monoclonal antibodies contain high levels of agalactosylated glycans (Jefferis 2012; Batra and Rathore 2016) as well as a discrete amount of high mannose glycans. This is presumably attributable to decreased glycan processing, culture process parameters, e.g., low dissolved oxygen (DO) concentration, or a reduced culture reduction potential (CRP), which have been reported to decrease galactosylation (Dionne et al. 2017) . In addition, the presence of sialidases (Dorai and Ganguly 2014) and other glycosidases (Gramer and Goochee 1993) in the cell culture medium may further decrease the galactosylation/sialylation level of mAbs.
In commercial mAbs, the agalactosylated and the high-mannose glycans level may potentially confer an inflammatory and immunogenic potential especially in autoimmune diseases. The inflammatory potential may further be increased in the non-fucosylated agalactosylated component. In such conditions, it is likely that mAb therapeutics with increased levels of galactosylation and 2,6 sialic acid contents, would exhibit superior profiles in terms of safety, efficacy, PK and immunogenicity.
In addition to the Fc-glycosylation, approximately 10-20% of endogenous antibodies are also glycosylated in the variable domain of the Fab region, with glycans commonly having a different glycosylation profile than the Fc-glycans (Spiegelberg et al. 1970; Mimura et al. 2007 ). The fact that the glycans in the variable domain are generally more exposed than the Fc-glycans raises safety concerns when non-human glycan residues such as N-glycolylneuraminic acid (NGNA) and galactose-α-1,3-galactose (α-gal) are involved (Spiegelberg et al. 1970) . Therefore, mAb glycosylation is a relevant CQA (Reusch and Tejada 2015) to be tightly monitored in the NBE (New Biological Entities) development, in comparability studies following manufacturing changes, and in the biosimilar development (comparability with the reference medicinal product).
In summary, several concerns associated with commercial mAb preparations could be addressed by closer mimicking physiological, human-like glycosylation patterns.
Therapeutic mAb manufacturing -current state of the art
The development of therapeutic mAbs is a lengthy and expensive process. Manufacturers are facing increasing demands in product quality and affordable drugs by authorities. Moreover, the emergence of biosimilars exerts additional cost pressure. In conventional biopharmaceutical manufacturing processes, it is generally accepted that the process itself defines the product which is characterized by numerous quality attributes. Among these, glycosylation is an important subset as it has profound effects in terms of efficacy and safety.
Mammalian host systems are the preferred expression platforms because they allow for the highest level of posttranslational processing and functional activity of the protein. The most prominent host cell lines currently used for marketed products are Chinese Hamster Ovary (CHO) or mouse myeloma (NS0, SP2/0) cell lines (Dumont et al. 2016; Kunert and Reinhart 2016) . However, as a consequence, their glycosylation profiles may differ significantly from those produced in human cells, raising concerns regarding immunogenicity and safety, e.g., due to the potential presence of non-human α-Gal or NGNA residues introduced by mouse cells (Chung et al. 2008; Jefferis 2009 ) and, at lower levels, also in CHO (Bosques et al. 2010; Montjovent et al. 2017) . For example, administration of mAbs containing α-Gal in patients with pre-existing IgE antibodies directed against the α-Gal epitope can lead to hypersensitivity reactions (Platts-Mills et al. 2015) .
When antibodies are produced at industrial scale, the N-glycosylation machinery of the host cell lines define the key Fc-glycan structure (Dell and Morris 2001) . The glycosylation processing within the cells involves a complex series of enzymatic reactions catalyzed by membrane-bound glycosidases (stepwise trimming) and glycosyltransferases (stepwise addition of new sugar) (Helenius and Aebi 2001) . Attached key glycans depend on the cell type and the physiological status of the cell; the expression and the activity of the cellular enzymes are exquisitely sensitive to events which take place within the cell. Depending on the extension of processing, the N-glycans are diversified in the Golgi apparatus in high mannose, hybrid and complex type (Shi and Goudar 2014) (Figure 3) , and the transition from hybrid-to complex-type further stabilizes the Fc region (Bowden et al. 2012) .
Culture media components and process parameters such as pH, temperature, etc. may also affect glycan composition (Batra and Rathore 2016; Liu, Nowak, et al. 2016 ). In addition, once a glycoprotein is secreted, glycosidases (e.g., sialidases) released by lysed cells, especially at a later stage of the bioprocess, may remove terminal glycan residues (Gramer and Goochee 1993; Dorai and Ganguly 2014) .
Depending on the cell type and process, the principle structures emerging are high mannose, hybrid, and complex type (see Figure 3 ). Within complex type glycans, the overall composition and structure may vary significantly, e.g., through the presence/absence of core fucose, the degree of terminal galactosylation (G0, G1, G2), the presence/absence and type of terminal sialic acid substitution N-acetylneuraminic acid (NANA), NGNA, the presence/absence of α-gal. The resulting glycan profile may lead to a differential impact on structure, stability, biological functions, pharmacokinetics, immunogenicity and safety.
One way to improve the antibody properties is to introduce a better control on the composition of the Fc-glycosylation, in particular, the reduction of fucosylation with the aim to increase ADCC. Current optimization efforts focus on host cell engineering and the cell culture conditions (Imai-Nishiya et al. 2007; El Mai et al. 2013; Brühlmann et al. 2017; Yang et al. 2015) . For example, to improve ADCC, a significant improvement through cell-based glycoengineering has been previously reported with the first approved mAbs mogamulizumab and obinutuzumab. Mogamulizumab (POTELIGEO ® , KW-0761) is a humanized mAb derived from Kyowa Hakko Kirin's POTELLIGENT ( ® ) technology which uses a α-1,6-fucosyltransferase (FUT8) knockout CHO cell line to produce mAbs with nonfucosylated glycan mixtures (Beck and Reichert 2012) . Obinutuzumab (Gazyva™, GA-101) is derived from Roche GlycoMAb ® technology which overexpresses β1,4-N-acetylglucosaminyltransferase III (GnTIII).
Once the GnT-III adds a bisecting GlcNAc to an oligosaccharide, the core-fucosylation is inhibited (Cameron and McCormack 2014) . Both technologies produce therapeutic mAbs with enhanced ADCC activity. Furthermore, the use of fluorinated fucose analogs as a specific inhibitor of fucosyltransferase was reported to substantially reduce core fucosylation of N-linked glycans in CHO cells (Rillahan et al. 2012; Brühlmann et al. 2015) and can therefore be expected to enhance ADCC activity of mAbs through rational media design. However, there are still some limitations with regards to maximized ADCC properties that can be obtained for oncology mAbs. Although this approach allows more control over the fucosylation level, these platforms still produce heterogeneous mixtures of the non-fucosylated glycoforms containing predominantly agalactosylated glycoforms, as reported for mogamulizumab. Elevated levels of the agalactosylated glycan variants result from impaired glycan processing since processing largely depends on the presence of core fucose and, consequently, non-fucosylated forms tend to be less processed (Castilho et al. 2015; Mimura et al. 2018) .
From a process economic point of view, the volumetric yields of mammalian cells are comparatively low compared to expression in other eukaryotic systems such as yeast. Yeast expression systems (e.g., Saccharomyces cerevisiae and Pichia pastoris) achieve rapid cell growth and high-protein yields with facile production scalability (Gerngross 2004) , and have most of the subcellular machinery for posttranslational modification present in higher eukaryotes. However, a key challenge associated with yeast expression is their production of high mannose glycans which may confer a short halflife and render proteins less efficacious and even immunogenic in humans (Dean 1999; Gemmill and Trimble 1999) . Therefore, cell line development efforts in yeast have focused on genetic modifications to reduce the high mannose content, and the production of glycoproteins, with humanized sialylated glycans, has been reported (Hamilton and Gerngross 2007) .
In summary, the glycan distribution defines to a large extent, the functional (with regards to effector functions) and safety profile of a manufactured mAb. The pain points resulting from current manufacturing processes may be summarized as follows. For patients, the efficacy and safety may be suboptimal, and manufacturers struggle with time-consuming process development, and inefficient manufacturing processes prone to process changes and batch-to-batch variability.
Current approaches to in vitro glycoengineering. Enzymatic glycoengineering refers to an in vitro modification of glycans with the aim to reduce glycan heterogeneity. The protocols typically employ (--) symbol between residues indicates a potential truncation contributing to the overall high Fc-glycan micro-heterogeneity. Complex type glycans containing 0, 1 or 2 galactose residues are referred as G0F, G1F and G2F glycoform when core-fucosylated and G0, G1 and G2 when core-fucose is absent. Non-human glycans are highly expressed by mouse cells and at low levels, by CHO cells.
enzymes targeting terminal sugar residues (neuraminidase, β(1,4) galactosidase, β(1,4) galactosyltransferase, and α(2,6) sialyltransferase) and suitable activated sugars (e.g., UDP-gal, CMP-NANA) to increase the galactosylation and/or sialylation level on mAbs. Thomann et al. describes the workflow of the in-solution modification of a monoclonal antibody at medium scale (Thomann et al. 2015) . Similarly, Tagyi reports the sequential enzymatic transformation on a solid-state matrix, e.g., protein A and G columns (Tagyi and Butler 2018) . The immobilization of the antibody in the latter approach facilitates the processing by allowing the enzymes and buffers to be washed out in repeated cycles of enzymatic reactions. The use of affinity resins commonly used in mAb purification may be further optimized for the implementation in large-scale manufacturing processes. However, although the end products may be derived from the same starting material, and despite the possibility to introduce "human-like" sialic acid with 2,6 linkages, such in vitro glycoengineering approaches are not able to deliver a truly homogeneous glycosylation. For example, this approach does not allow modifying high mannose glycans or transforming hybrid into complex glycans. Therefore, although enrichment of a desired complex glycan variant can be achieved, a certain overall heterogeneity arising from the presence of high-mannose and hybrid variants will remain in the final product. As a consequence, this methodology, in its current format, is not applicable to proteins expressed in wild-type yeast due to the high content of high mannose glycans. As a further limitation, although the target glycan is enriched, the final products contain also still heterogeneous mixtures of monosialylated and disialylated glycans and several rounds of enzymatic reactions may be required in order to reach the desired degree of sialylation (Thomann et al. 2015; Tagyi and Butler 2018) . Furthermore, some enzymatic reactions may lead to an increased level of Asn deamidation and Asp isomerization (Thomann et al. 2015) .
Homogeneous glycans and the "universal" glycan
The functional properties (e.g., ADCC) in therapeutic mAbs may be enhanced through Fc-glycoforms that are both non-fucosylated and hyper-galactosylated. However, the enhanced potency carries also the potential risk of an immunogenic reaction towards non-diseased cells also bearing the antibody target, underlining the importance of target specificity (Dekkers et al. 2017 ).
Wong coined the term "glycoantibody", referring to a homogeneous population of mAbs having a single, uniform glycoform on the Fc region (Wong et al. 2015) . The same group also coined the term "universal" glycan for the non-fucosylated, fully sialylated biantennary glycan chain (S2(α2,6)G2) which, when homogeneously added to a mAbs, confers several improved properties in terms of humanization of sialic acid linkage, significantly improved binding to the FcγRIIIa (both VV and FF polymorphisms), increased ADCC (while maintaining the binding properties to other receptors such as FcγRs and C1q), increased ADCC of S2(α2,6)G2 in comparison to S2(α2,3)G2, and a higher conformational plasticity between the open and closed Fc conformation (Lin et al. 2015; Chen et al. 2017 ). The closed conformation is suggested to optimize the binding properties to FcRn ), this in turn could result in a decreased clearance rate of mAbs. The latter feature can represent a differentiating factor between the glycan chains (S2(α2,6)G2) and G2. Further studies would be necessary to establish if the closed conformation of non-fucosylated (S2(α2,6)G2) enhance the binding properties with both the FcRn and the type II Fc receptors. The type II Fc receptors are known to confer anti-inflammatory properties to the closed conformation of fucosylated (S2(α2,6)G2F) antibodies (Sondermann et al. 2013 ).
It is worth noting that non-fucosylated glycoengineered mAbs not only maximize ADCC "in vivo", where a high amount of approximately 10 mg/mL of endogenous antibodies compete for the FcγRs but they can also enhance macrophage/monocyte induced ADCP activity (Herter et al. 2014) . ADCP is a well-recognized and relevant mechanism of action of therapeutic antibodies used in oncology (Weiskopf and Weissman 2015) .
Chemoenzymatic glycoengineering to obtain homogeneously glycosylated antibodies. Chemoenzymatic glycoengineering refers to an in vitro remodeling of glycans, employing enzymes such as endoglycosidases and glycosynthase. Details on such a platform can be found in the recent review by Mimura (Mimura et al. 2018) as well as in the protocol by Tang (Tang et al. 2017 ) on chemoenzymatic synthesis of glycoengineered IgG antibodies and glycosite-specific antibody-drug conjugates (ADCs). Briefly, chemoenzymatic glycoengineering is based on two enzymatic steps: the trimming of all the heterogeneous N-glycans by an endoglycosidase leaving the first GlcNac residue and the adding back a well-defined N-glycan with desired properties en bloc by glycosyntase mutants which, as a substrate, use a synthetic N-glycan core oxazoline. By co-expressing endoglycosidases (EndoH), the first step can potentially be omitted, as the deglycosylation occurs in vivo (Bennett et al. 2018 ). This platform has a high flexibility with the potential to produce nonfucosylated, fucosylated and functionalized Fc glycans.
The platform may be applied to both mAbs, antibody mixtures such as IVIGs (e.g., to obtain highly sialylated (>90%) IVGs), and as a functionalization platform to produce ADCs or other labeling modifications. The feasibility of this approach has been reported by several groups (see next section). Furthermore, it has been shown that this approach, apart from the specific transformation of the mAb glycans, does not affect other posttranslational modifications (Liu, Giddens, et al. 2016) . Until now, this platform has mainly been employed to generate symmetric and homogeneous glycosylation populations for structural and functional studies (Kurogochi et al. 2015; Lin et al. 2015) .
Case studies. Chemoenzymatic glycoengineering platforms were successfully employed by several groups, amongst which Academia Sinica, National Taiwan University, CHO Pharma Inc. (Taiwan) and the University of Maryland, Rockefeller University (USA) have produced pivotal papers (Zou et al. 2011; Huang et al. 2012; Lin et al. 2015; Tang et al. 2016 Tang et al. , 2017 Li, Zhu, et al. 2017) . A few of these published studies use commercial mAbs as reference models, e.g., Rituxan (rituximab) (Lin et al. 2015; Li, DiLillo, et al. 2017) , Herceptin (trastuzumab) (Kurogochi et al. 2015; Lin et al. 2015; Chen et al. 2017; Li, DiLillo, et al. 2017; Liu et al. 2018) and Humira (adalimumab) .
A common important finding reported in these studies, although the actual fold increase differed, was that the glycoengineered mAbs with a homogeneous glycosylation showed clearly enhanced FcγRIIIa binding compared to heterogeneously glycosylated reference samples (wild-type) (Lin et al. 2015; Li, DiLillo, et al. 2017) . Moreover, FcγRIIIa binding was found to be consistently higher in the non-fucosylated form of the molecule (both G2 and S2(α2,6)G2) in comparison not only to wildtype but also in comparison to the glycoengineered mAbs which contain homogeneous non-fucosylated agalactosylated and M3 glycoforms (Lin et al. 2015) (Figure 4) . Some patients may become resistant to rituximab due to high dosage and long-term use. It has been shown "in vitro" that rituximab resistant cells are, however, still sensitive to glycoengineered mAb (S2 (α2,6)G2) presumably due to their higher affinity (Lin et al. 2015) . The S2(α2,6)G2 and the G2 glycoengineered mAbs maximize ADCC but can also enhance ADCP (Herter et al. 2014 ). The benefits of glycoengineered mAbs in terms of enhanced ADCC and ADCP activity in presence of competitive endogenous antibodies due to their enhanced binding to FcγRIII are worth underlining; in addition, Chen demonstrated the differential binding activity to FcγRIIIa of trastuzumab in absence/presence of the target . In presence of the target, a strong decrease in affinity was observed for wildtype trastuzumab (Kd = 24 nM → Kd = 169 nM), while the decrease was minimal for the glycoengineered trastuzumab (S2(α2,6)G2) (Kd = 10 nM → Kd = 20 nM). Due to the Fc conformational plasticity (open/closed conformation) induced by S2(α2,6)G2, and/or differential impact of G2 vs. G0 on Fabs orientation (distribution of directional and rotational vectors), one can speculate that, similarly to the FcγRIII binding site, the binding sites for the other FcγRs and C1q, may also be less affected by the presence of the target ligands. If confirmed, this may translate in higher effector function (ADCC, ADCP and CDC) in the tumor microenvironment of S2(α2,6)G2and G2 glycoengineered mAbs.
Glycoengineering was also applied to IVIGs with the aim of increasing the 2,6-sialic acid content (from <10% to >90%). Furthermore, the platform is also applicable to the generation of functionalized glycans, suitable for click-chemistry for the targeted introduction of payloads, e.g., cytotoxic drug development (e.g., antibody-drug conjugates, ADCs), or for labeling and tracers for in vitro and in vivo cell imaging, immunohistochemistry and western blotting (Huang et al. 2012; Tang et al. 2017) .
Finally, first clinical trials are planned applying glycoengineered mAbs. CHO Pharma Inc., a Taiwan-based start-up company, has applied its proprietary glycan-based technology platforms to develop truly homogeneously glycosylated therapeutics that are intended as "biobetters" of currently marketed antibodies. A Phase I open-label, multiple-dose study of a glycoengineered anti-CD20 antibody (Trial ID: NCT03221348) has been planned to start in March 2018 for Refractory or Relapsed Follicular Lymphoma indication while others are in pre-clinical development phases.
Some suppliers already commercialize reagents that are required for glycan engineering. For example, Fushimi Pharmaceutical Co.
Ltd. (Japan) offers enzymes and substrates for the targeted remodeling of protein glycans at lab scale. Genovis (Sweden) commercializes soluble and immobilized enzymes required for deglycosylation of mAbs (up to 100 mg scale), as well as kits with broader applications such as cytotoxic drug development, in vitro and in vivo cell imaging, immunohistochemistry and western blotting.
Chemoenzymatic glycoengineering -advantages. The pain points associated with current manufacturing processes, i.e., the suboptimal safety and efficacy, and batch-to-batch inconsistencies, could collectively be addressed by having maximum control over the Fc-glycosylation of the end products. For example, instead of relying on the host cell machinery, the chemoenzymatic glycoengineering approach is a radically novel effort in which the glycans that are attached during the cell culture phase are entirely remodeled by replacing them with those optimal for the target application, e.g., humanized N-glycans, maximized efficacy. In this manner, the final product can be produced with precisely defined and desired glycan profiles, e.g., homogeneous, human-like glycans with enhanced biological properties. Moreover, the resulting glycan profile is also uncoupled from the process, i.e., independent from the expression host, and unaffected by process variations and changes.
The chemoenzymatic glycoengineering approach offers thus several significant advantages.
• Maximized efficacy -Studying homogeneous glycan populations in Rituximab, Lin et al. (2015) has shown that non-fucosylated and completely galactosylated (G2) or human-like sialylated mAbs (S2(α2,6)G2) are superior (approx. 4-6-fold higher FcγRIIIa binding compared with non-fucosylated agalactosylated glycans (G0) and high mannose variants. Compared to the heterogeneous wildtype glycan population, an increase in terms of the FcγRIIIa binding of up to 20-fold was observed for the homogeneous S2(α2,6)G2 variant. Analogous to Li, DiLillo, et al. (2017) , who observed a correlation between in vitro binding and The homogeneous glycan populations, using rituximab and trastuzumab as model proteins, were obtained by chemo-enzymatic glycoengineering (Lin et al. 2015) .
enhanced in vivo activity (Li, Zhu, et al. 2017) , it can be expected that the maximized binding translates into maximized in vivo efficacy. This emphasizes that an antibody, which is chemoenzymatically engineered for a particular homogeneous glycan population, is not only superior to currently marketed mAbs carrying a conventional, heterogeneous glycan population, but also superior compared with low-fucose products derived from processes with glycosylation improvements on the cell-line level.
• Maximized safety -Chemoenzymatic glycoengineering allows precise control over the glycan structures present in a product. Therefore, any potential presence of non-human variants, high mannose and undesired agalactosylated glycans can be remodeled. Moreover, the precise tuning of the glycan content allows avoiding immunogenicity and adverse reactions due to preexisting antibodies in patients, e.g., anti-α-Gal, anti-NGNA, antiagalactosyl (Ichikawa et al. 1998; Nishijima et al. 2001; Teranishi et al. 2002; Zhu and Hurst 2002; Lu et al. 2007; Macher and Galili 2008) .
• Increased process flexibility and efficiency -○ Facilitated process development -Development is shortened timewise because less time would be required to fine-tune the fermentation conditions to achieve a desired glycosylation profile. The pivotal role of the intracellular functions of Nlinked glycans in terms of protein folding, oligomerization, quality control, sorting, and transport is retained with this platform (Helenius and Aebi 2001) . Differently glycosylated end products can be produced from the same intermediate bulk. Furthermore, the approach can facilitate also functional studies when applied to current products. ○ Free choice of expression host -The production of glycosylated mAbs is no longer restricted to mammalian cells. Instead, other eukaryotic expression hosts or even plant cells could thus be selected for maximum productivity (Bennett et al. 2018; Liu et al. 2018 ). ○ More robust processes and increased batch-to-batch consistency -During the re-modeling of the glycan profile, after the fermentation, any change in glycosylation, because of a process change, will be normalized.
Chemoenzymatic glycoengineering -challenges and limitations. Current manufacturing plants and analytical methods are not optimized for the application of this platform and should be redesigned to apply this procedure in the most effective way. Additional processing steps, glycan removal and re-attachment will be required for glycan remodeling. The additional use of enzymes and oligosaccharide reagents poses the risk to introduce additional HCPs or process related impurities. This will necessitate additional analytical methods to monitor their clearance and may require additional purification steps to remove newly introduced process related impurities. The handling times, additional equipment and reagents will add to the overall manufacturing costs, although implementation of chemoenzymatic glycoengineering may be facilitated by the integration of additional processing steps into existing operations, e.g., enzymatic reactions on solid-phases like protein A columns (Tagyi and Butler 2018) .
Currently, enzymes and oligosaccharide reagents are not yet commercially available at relevant production scales. However, once dedicated equipment and reagents will be produced for mAb manufacturing, their unit costs will go down with scale.
Conclusions and perspectives
Chemoenzymatic glycoengineering is emerging as a radical and attractive approach to gain unprecedented control over the glycosylation profile of mAbs. It therefore offers the possibility to generate mAbs with precisely defined and desired glycans, resulting in superior product quality and safety, or in other targeted functionalisation such as ADCs.
Additional processing costs will be offset by a significant costsaving potential, due to the possibility of more economic process formats with significantly higher volumetric productivities (Kurogochi et al. 2015; Liu et al. 2018) .
Currently, this platform is focused on Fc-glycans, however, by using suitable reagents and enzymes, it may become generally applicable to glycoproteins as a platform for glycan remodeling to generate superior products. For example, it has been suggested that among interferon-beta-1a glycoforms those with higher-antennarity could better sustain bioactivity over time (Mastrangeli et al. 2014) .
Once the first glycoengineered antibody, obtained by this approach, will demonstrate to be superior in the clinic use, and customized reagents and equipment will be commercially available at affordable costs and in-line with regulatory requirements, the platform is likely to become a breakthrough, paving the way for the development and production of the next-generation of immunotherapeutics.
